Pharma Deals Review, Vol 2006, No 76 (2006)

Font Size:  Small  Medium  Large

Salix Licenses Right to Market and Distribute Sanvar® from Debiopharm

Business Review Editor

Abstract


Salix Pharmaceuticals and Debiopharm entered into license agreement to sell, market and distribute Salix’s Sanvar® (vapreotide acetate) for treating acute oesophageal variceal bleeding (AOVB). The deal could be worth up to US$14 M to Debiopharm.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.